Acarbose
Also known as: Precose
Classification
Pharmaceutical
Regulatory Status
FDA-approved prescription product or labeled drug class
Sources
1
Review
n/a
Overview
Acarbose is represented by its commonly described alpha-glucosidase inhibitor mechanism. This conservative launch record supports search and overlap detection, not medical recommendation.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
Labeled oral alpha-glucosidase inhibitor studied and approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults.
Interactions & cautions
Drug interactions
digestive enzyme products (amylase, pancreatin) — May reduce acarbose effect when co-administered. (review)
insulin or insulin secretagogues — Increased hypoglycemia risk; glucose treatment choice differs if acarbose is on board (use glucose, not complex carbs alone). (high)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw